(本文来自第一财经) 白云山公告，公司合并报表范围内企业广州白云山生物制品股份有限公司收到国家药品监督管理局核准 签发关于冻干人用狂犬病疫苗（Vero细胞）的《药品注册证书》。截至目前，白云山生物在冻干人用狂 犬病疫苗（Vero 细胞）研发项目上已投入研发费用合计约人民币20509万元（未经审计）。 ...

证券代码：600332 证券简称：白云山 公告编号：2025－094 广州白云山医药集团股份有限公司 关于广州白云山生物制品股份有限公司收到 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 合并报表范围内企业广州白云山生物制品股份有限公司（以下简称 "白云山生物"）收到国家药品监督管理局核准签发关于冻干人用狂 犬病疫苗（Vero 细胞）的《药品注册证书》。现将相关情况公告如 下： 一、药品的基本情况 药品通用名称：冻干人用狂犬病疫苗（Vero 细胞） 剂型：注射剂 规格：复溶后每瓶 0.5ml。每 1 次人用剂量为 0.5ml，狂犬病疫 苗效价应不低于 2.5IU。 注册分类：预防用生物制品 证书编号：2025S03950 药品注册标准编号： 上市许可持有人：（1）名称：广州白云山生物制品股份有限公 司；（2）地址：广州市经济技术开发区连云路 406 号 生产企业：（1）名称：广州白云山生物制品股份有限公司；（2） 地址：广州市番禺区万宝北街 1 ...

Core Viewpoint - Baiyunshan (600332.SH) has received approval from the National Medical Products Administration for the registration of its freeze-dried human rabies vaccine (Vero cells), which is an effective method for preventing rabies [1] Company Summary - Baiyunshan's subsidiary, Guangzhou Baiyunshan Biological Products Co., Ltd., is the entity that received the drug registration certificate for the rabies vaccine [1] - The rabies vaccine is intended for the prevention of rabies, a serious infectious disease caused by the rabies virus, primarily transmitted through bites or scratches from infected animals such as dogs and cats [1] Industry Summary - The approval of the rabies vaccine aligns with the industry's focus on developing effective vaccines to control and prevent infectious diseases [1]

每经AI快讯，白云山（SH 600332，收盘价：25.85元）12月25日晚间发布公告称，近日，广州白云山医 药集团股份有限公司合并报表范围内企业广州白云山生物制品股份有限公司收到国家药品监督管理局核 准签发关于冻干人用狂犬病疫苗的《药品注册证书》。产品名称为"冻干人用狂犬病疫苗"。 2025年1至6月份，白云山的营业收入构成为：大商业占比69.32%，大健康占比16.79%，大南药占比 12.53%，其他占比1.07%，其他业务占比0.3%。 每经头条（nbdtoutiao）——对话马斯克脑机接口"一号受试者"：大脑植入芯片23个月，我正重新夺回 人生的独立 （记者 曾健辉） 截至发稿，白云山市值为420亿元。 ...

每经AI快讯，12月25日，白云山（600332）(600332.SH)公告称，公司合并报表范围内企业白云山生物 收到国家药品监督管理局核准签发的冻干人用狂犬病疫苗（Vero细胞）的《药品注册证书》。该疫苗用 于预防狂犬病，白云山生物已投入约2.05亿元研发费用。 ...

来源：新浪证券-红岸工作室 12月23日，白云山涨0.12%，成交额2.36亿元。两融数据显示，当日白云山获融资买入额2008.77万元， 融资偿还3360.92万元，融资净买入-1352.15万元。截至12月23日，白云山融资融券余额合计9.20亿元。 融资方面，白云山当日融资买入2008.77万元。当前融资余额9.18亿元，占流通市值的2.53%，融资余额 超过近一年80%分位水平，处于高位。 融券方面，白云山12月23日融券偿还200.00股，融券卖出4.46万股，按当日收盘价计算，卖出金额 115.16万元；融券余量9.79万股，融券余额252.78万元，超过近一年80%分位水平，处于高位。 资料显示，广州白云山医药集团股份有限公司位于广东省广州市荔湾区沙面北街45号,香港金钟道89号 力宝中心第2座20楼2005室，成立日期1997年9月1日，上市日期2001年2月6日，公司主营业务涉及中西 成药、化学原料药、天然药物、生物医药、化学原料药中间体的研究开发、制造与销售;西药、中药和 医疗器械的批发、零售和进出口业务;大健康产品的研发、生产与销售;及医疗服务、健康管理、养生养 老等健康产业投资等。主营 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《关连交易 - 参与设立广药广开基金和广药荔湾基金》 《海外监管公告》 《海外监管公告》 《新持续关连交易协议》 《海外监管公告》 最新公告列表 截至2025年12月23日收盘，白云山（00874）报收于18.44元，较前一交易日下跌0.7%，该股当日开盘 18.53元，最高18.63元，最低18.44元，成交额达1901.73万元。近52周最高20.4元，最低15.01元。 近日，广州白云山医药集团股份有限公司发布公告称，公司董事会批准附属企业广药二期基金与广药资 本、广开基金订立合伙协议一，三方分别出资人民币9,750.00万元、250.00万元、10,000.00万元，共同 设立目标规模为人民币3.00亿元的广州广药广开创业投资基金（暂定名）。同日，董事会批准广药二期 基金与广药资本、天使母基金、荔湾产投基金订立合伙协议二，四方分别出资人民币9,950.00万元、 350.00万元、9,850.00万元、9,850.00万元，共同设立规模为人民币3.00亿元的广州荔湾广药创业投资 ...

Group 1 - The Ministry of Finance and another department issued opinions to implement the State Council's notice on domestic product standards in government procurement, defining that domestic products must be produced within the borders of China [1] - The notice specifies that products produced in special customs supervision areas, such as bonded zones, are considered produced in China, and medical devices with the necessary registration certificates are also included [1] Group 2 - The international gold and silver markets continue to reach new highs, with COMEX gold futures rising by 2.13% to $4480.6 per ounce and silver futures increasing by 2.37% to $69.09 per ounce [2] - Major U.S. stock indices saw gains, with the Dow Jones Industrial Average up 0.47%, the S&P 500 up 0.64%, and the Nasdaq Composite up 0.52%, indicating a positive market trend [2] Group 3 - The National Medical Products Administration released the "Internet Drug and Medical Device Information Service Filing Management Regulations," which will standardize the filing process for internet-based medical services [3] - This regulation aims to guide local authorities in managing the filing process effectively, impacting pharmaceutical e-commerce platforms in Hong Kong [3] Group 4 - Hong Kong's Financial Secretary highlighted the region's significant potential in developing a commodities market, emphasizing its role in serving both national and global needs [4] - The global supply and demand dynamics for various commodities are undergoing profound changes driven by geopolitical factors, technological advancements, and green transitions [4] Group 5 - The Hong Kong Gold Central Clearing System is set to begin trial operations in 2026, with plans for a significant expansion of gold storage capacity at the airport [5] - The government will establish a preparatory group to involve local and international stakeholders in the development of this industry organization [5] Group 6 - NVIDIA's GB300 AI server cabinet is projected to reach a shipment volume of 55,000 units in the next year, driven by major companies like Microsoft and Meta, marking a 129% year-on-year increase [6] - The next-generation Vera Rubin 200 platform is expected to start shipping in Q4 of next year, providing growth momentum for supply chain manufacturers [6] Group 7 - China National Nuclear Corporation announced that its Huizhou Unit 1 is now expected to be operational in the first half of 2026, with both Units 1 and 2 currently in the debugging phase [9] - The operational timeline for these units has been adjusted from previous estimates, reflecting careful consideration of project progress [9] Group 8 - China National Offshore Oil Corporation signed a strategic cooperation agreement with Datang Hainan to develop a green methanol project in Danzhou, with a planned production capacity of 100,000 to 200,000 tons per year [10] - This collaboration aims to explore high-value utilization of biomass and establish a supply chain for green methanol in the region [10] Group 9 - Huayu-B announced that its CSF-1R inhibitor, Beijiemai®, has been approved by China's NMPA for treating symptomatic tenosynovial giant cell tumors in adult patients [11] - The approval will enable Merck to expedite the availability of this product to Chinese patients [11] Group 10 - Sanhua Intelligent Control expects its annual net profit to increase by 25% to 50%, projecting a profit of approximately 3.874 billion to 4.649 billion yuan [12] - The company's net profit, excluding non-recurring gains and losses, is expected to be between 3.679 billion and 4.615 billion yuan, reflecting strong financial performance [12] Group 11 - China Duty Free Group is set to benefit significantly from the recent launch of the Hainan Free Trade Port, with a notable increase in duty-free shopping sales [16] - On the first day of the port's operation, duty-free shopping in Hainan reached 161 million yuan, marking a 61% year-on-year increase [16]

（文章来源：证券日报） 证券日报网讯 12月22日晚间，白云山发布公告称，公司第九届董事会第三十二次会议审议通过《关于 本公司2026年度日常关联交易预计数的议案》等多项议案。 ...

Group 1 - The core point of the article is that Baiyunshan (00874.HK) has approved a partnership agreement for the establishment of the Guangyao Guangkai Fund, with contributions from various entities totaling RMB 1.225 billion [1] - Baiyunshan's stock closed at HKD 18.57 on December 22, 2025, reflecting a decrease of 0.38% with a trading volume of 846,000 shares and a turnover of HKD 15.673 million [1] - The company has a market capitalization of HKD 40.99 billion, ranking 5th in the Traditional Chinese Medicine II industry [1] Group 2 - The investment banks predominantly rate Baiyunshan as "Buy," with one investment bank issuing a "Buy" rating in the last 90 days [1] - The latest report from Great Wall Securities also gives Baiyunshan a "Buy" rating [1]